CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

​Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the A